MASTL targeting specifically and importantly potentiated non-small cell lung cancer cells to cell death in chemotherapy, while sparing normal cells [1], revealing that MASTL upregulation helps promote cancer progression and tumor recurrence after initial cancer therapy, and strongly supporting MASTL as a promising target of increased therapeutic efficacy of anti-cancer therapies, including anti-CRC therapy. This evidence concerns the gene MASTL and neoplasm.